Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

FHS
May 16, 2024
11:47 am

Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled ‘Clinical evaluation of EasyM™ for disease response analysis in newly diagnosed MM patients (NDMM)’.

Unmasking the ‘centricity’ illusion in clinical trials

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the

May 24, 2024

FDA grants fast track status for Ambrx’s prostate cancer treatment

APEX-01 is enrolling patients with tumours that have advanced following treatment with a minimum of two FDA-approved prostate cancer therapies. Credit: Peakstock / shutterstock.com. The

July 20, 2023

Zerva acquires Acer Therapeutics to bolster rare disease portfolio – Pharmaceutical Technology

The news caused Acer’s stock to skyrocket by 140% when the markets opened on 31 August. Image Credit: 3rdtimeluckystudio / Shutterstock. Zerva Therapeutics, formerly KemPharm,

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.